User login
Key clinical point: Trastuzumab emtansine (T-DM1) led to superior survival outcomes compared with lapatinib plus capecitabine (LC) in patients with breast cancer brain metastases (BCBM).
Major finding: After a median follow-up of 30.7 months, overall survival was significantly improved with T-DM1 vs LC (hazard ratio 0.55; P = .013), with significant improvements observed in other endpoints, such as time to next relevant treatment or death (P = .005) and real-world progression-free survival (P < .001).
Study details: Findings are from a real-world study including 214 patients with HER2+ BCBM who initiated treatment with T-DM1 (n = 161) or LC (n = 53).
Disclosures: This study was funded by F. Hoffmann-La Roche. Three authors declared being employees of and owning stocks in Roche. The other authors declared receiving honoraria, consulting, or advisory fees from, being employees of, or owning stocks in other sources.
Source: Sanglier T et al. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast. 2023 (Jan 15). Doi: 10.1016/j.breast.2023.01.007
Key clinical point: Trastuzumab emtansine (T-DM1) led to superior survival outcomes compared with lapatinib plus capecitabine (LC) in patients with breast cancer brain metastases (BCBM).
Major finding: After a median follow-up of 30.7 months, overall survival was significantly improved with T-DM1 vs LC (hazard ratio 0.55; P = .013), with significant improvements observed in other endpoints, such as time to next relevant treatment or death (P = .005) and real-world progression-free survival (P < .001).
Study details: Findings are from a real-world study including 214 patients with HER2+ BCBM who initiated treatment with T-DM1 (n = 161) or LC (n = 53).
Disclosures: This study was funded by F. Hoffmann-La Roche. Three authors declared being employees of and owning stocks in Roche. The other authors declared receiving honoraria, consulting, or advisory fees from, being employees of, or owning stocks in other sources.
Source: Sanglier T et al. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast. 2023 (Jan 15). Doi: 10.1016/j.breast.2023.01.007
Key clinical point: Trastuzumab emtansine (T-DM1) led to superior survival outcomes compared with lapatinib plus capecitabine (LC) in patients with breast cancer brain metastases (BCBM).
Major finding: After a median follow-up of 30.7 months, overall survival was significantly improved with T-DM1 vs LC (hazard ratio 0.55; P = .013), with significant improvements observed in other endpoints, such as time to next relevant treatment or death (P = .005) and real-world progression-free survival (P < .001).
Study details: Findings are from a real-world study including 214 patients with HER2+ BCBM who initiated treatment with T-DM1 (n = 161) or LC (n = 53).
Disclosures: This study was funded by F. Hoffmann-La Roche. Three authors declared being employees of and owning stocks in Roche. The other authors declared receiving honoraria, consulting, or advisory fees from, being employees of, or owning stocks in other sources.
Source: Sanglier T et al. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast. 2023 (Jan 15). Doi: 10.1016/j.breast.2023.01.007